Comments Kymera Therapeutics (NASDAQ:KYMR) stated on Monday that it has commenced an underwritten public offering of $500M of shares, and the underwriters will have a 30-day option to purchase up to an additional $75M of shares of its common stock. The Recommended For You More Trending News See More ยป Post navigation Dyne Therapeutics announces $300M proposed public offeringVera Therapeutics announces $200M public offering
